DJIA 16,804.71 -238.19 -1.40%
NASDAQ 4,422.09 -71.31 -1.59%
S&P 500 1,946.16 -26.13 -1.32%
market minute promo

Roche Holding Ltd. (ADR) (NASDAQOTH: RHHBY)

36.74 -0.25 (-0.68%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

RHHBY $36.74 -0.68%
Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $37.14
Previous Close $36.99
Daily Range $36.65 - $37.17
52-Week Range $31.75 - $38.71
Market Cap $206.5B
P/E Ratio 0.00
Dividend (Yield) $0.00 (2.5%)
Volume 3,037,836
Average Daily Volume 1,513,613
Current FY EPS $2.03





Roche Holding Ltd. (ADR) (RHHBY) Description


News & Commentary

Switzerland's Prescription Drug Tactics Should Make Americans Jealous

Prescription drug costs in Switzerland are more than 40% lower than the U.S. on a per capita basis, yet the Swiss government is looking to lower those costs even further. Find out what benefits and risks could await its approach.

3 Reasons Illumina, Inc.'s Stock Could Rise

It's the leader in a fast-growing young industry, but does Illumina (ILMN) have what it takes to trounce the market over the long term?

Breast Cancer Occurs Most Often in These 5 States

Breast cancer was diagnosed in more than 220,000 women in 2011. Find out in which five states a breast cancer diagnosis is the most common, as well as what current and developing therapies are being used to treat this terrible disease.

Organovo Holdings Inc Stock: 3 Crucial Pieces of Information Revealed

While investors need to wait to hear how Organovo's liver assays sell, the company is giving us a taste of the future.

Why ImmunoGen, Inc. Stock Crashed 22% in 2014

While the S&P Biotech index soars, ImmunoGen shareholders are getting left in the dust. Find out what's been holding shares back in 2014, and whether or not ImmunoGen will rebound from its current price.

Why Exelixis Inc. Stock Crashed By 70% in 2014

Exelixis stock got mauled after its lead drug failed to impress in a key late-stage study. Find out whether there's any hope left for this biotech stock or if it's time for investors to kiss it goodbye.

Why Inovio Pharmaceuticals Inc. Plunged By 10% in 2014

Cancer immunotherapy vaccine developer Inovio Pharmaceuticals has largely underperformed the market in 2014. Find out what's keeping the stock down and whether or not Inovio shares are poised for a rebound.

The Surprising 7 States Where Melanoma Most Often Occurs

Of the seven most common types of cancer, melanoma incidence was the only one to rise between 2000 and 2009. Find out in which seven states melanoma occurs most often, as well as what's being done to curb this terrible form of skin cancer.

Why Exelixis Inc. Stock Plunged

Exelixis' stock is among today's biggest losers after its late-stage prostate cancer trial failed to meet its primary endpoint. See what shareholders should be focused on going forward.

Is It Time to Buy Johnson & Johnson's Stock?

Successful new drug launches have fueled Johnson & Johnson's run, but is there enough left in the tank for shares to continue heading higher?

See More RHHBY News...

RHHBY's Top Competitors

RHHBY $36.74 (-0.68%)
Current stock: RHHBY
JNJ $104.30 (-2.15%)
Current stock: JNJ
NVS $93.22 (-0.97%)
Current stock: NVS
GSK $45.90 (-0.15%)
Current stock: GSK